328 related articles for article (PubMed ID: 28093620)
21. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
23. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
24. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
25. [Immune-related adverse events of immune checkpoint inhibitors].
Tadano H; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
[TBL] [Abstract][Full Text] [Related]
26. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
27. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
28. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Oweira H
Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):218-230. PubMed ID: 27894673
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
30. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Ramagopal UA; Liu W; Garrett-Thomson SC; Bonanno JB; Yan Q; Srinivasan M; Wong SC; Bell A; Mankikar S; Rangan VS; Deshpande S; Korman AJ; Almo SC
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4223-E4232. PubMed ID: 28484017
[TBL] [Abstract][Full Text] [Related]
32. Current and Emerging Perspectives on Immunotherapy for Melanoma.
Daud A
Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
[TBL] [Abstract][Full Text] [Related]
33. Are virus-induced cancers more sensitive to checkpoint inhibitors?
Kanaan H; Kourie HR; Awada AH
Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334
[No Abstract] [Full Text] [Related]
34. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
35. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
Iglesias P
Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
[TBL] [Abstract][Full Text] [Related]
37. The development of immunotherapy in older adults: New treatments, new toxicities?
Helissey C; Vicier C; Champiat S
J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
[TBL] [Abstract][Full Text] [Related]
38. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.
Cuzzubbo S; Javeri F; Tissier M; Roumi A; Barlog C; Doridam J; Lebbe C; Belin C; Ursu R; Carpentier AF
Eur J Cancer; 2017 Mar; 73():1-8. PubMed ID: 28064139
[TBL] [Abstract][Full Text] [Related]
39. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
40. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Immunotherapy; 2015; 7(11):1213-27. PubMed ID: 26513491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]